Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Faster-acting Insulin Aspart in Type 1 Diabetes
NCT02131246Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Mean plasma glucose concentration. Started May 2014; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02131246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131246.